News and views
March 2012 Br J Cardiol 2012;19:15
Correspondence: Iodine deficiency and cholesterol
Correspondence from the world of cardiology....
March 2012 Br J Cardiol 2012;19:15
Correspondence: Specialty training
Correspondence from the world of cardiology....
March 2012 Br J Cardiol 2012;19:18–9
Up to your neck in it
We continue our series in which Consultant Interventionist Dr Michael Norell takes a sideways look at life in the cath lab…and beyond. In this column, he considers a useful accessory....
February 2012 Br J Cardiol 2012;19:16 Meeting report
Care for the individual patient
The 14th British Society for Heart Failure (BSH) annual meeting, entitled ‘Care for the individual patient’, was held in late November at the Queen Elizabeth Conference Centre in London. Attracting 400 delegates with its multidisciplinary programme, Dr Dominic Kelly reports on the highlights....
October 2011 Br J Cardiol 2011;18:203
Changes to hypertension guidelines
The National Institute for Health and Clinical Excellence (NICE) has updated its guideline on hypertension, making a number of new recommendations regarding both the diagnosis and treatment of the condition. The new clinical guideline 127 updates and replaces clinical guideline 34, which was published in June 2006....
October 2011 Br J Cardiol 2011;18:203
Dronedarone to be restricted
The European Medicines Agency has recommended that the anti-arrhythmic, dronedarone (Multaq®), should be restricted....
October 2011 Br J Cardiol 2011;18:203
Rivaroxaban reduces events in ATLAS-ACS
Bayer has announced that the oral anticoagulant, rivaroxaban, has reduced ischaemic events but increased bleeding in acute coronary syndrome (ACS) patients in the large-scale trial ATLAS-ACS 2 TIMI 51. The … Continue reading Rivaroxaban reduces events in ATLAS-ACS →...
October 2011 Br J Cardiol 2011;18:208–210
News from the ESC Congress 2011
Highlights of the European Society of Cardiology (ESC) 2011 Congress, held in Paris, France, from 27th–31st August, included encouraging results with the third new oral anticoagulant alternative to warfarin for patients with atrial fibrillation, a treatment for recurrent endocarditis, and the suggestion that six months dual antiplatelet therapy may be enough after drug-eluting stent placement....
October 2011 Br J Cardiol 2011;18:212-213 Meeting report
Quality in CVD care – taking the lead in the new NHS
This year’s 14th Annual Scientific Meeting of the Primary Care Cardiovascular Society (PCCS), held in Bristol, 28th–30th September 2011, highlighted the controversial reforms in the new NHS as well as rounding up new developments in cardiovascular care. Tim Kelleher reports....
